ECO Animal Health Group is a global animal health business specializing in the research, development, registration, manufacturing and commercialization of parasiticides and vaccines for both livestock and companion animals. The company’s product portfolio includes endectocides, acaricides and vaccine solutions designed to help farmers and veterinarians manage parasites and diseases in cattle, sheep, goats, horses, poultry and pets. ECO Animal Health places strong emphasis on scientific formulation and regulatory compliance, supporting its offerings with technical services and field support to optimize animal health and productivity.
Flagship products include a range of macrocyclic lactone endectocides used to control gastrointestinal roundworms, lungworms and external parasites in ruminants and equines, as well as acaricidal treatments for poultry. The company has also developed vaccines targeting key livestock pathogens to reduce reliance on antimicrobials and improve herd immunity. ECO Animal Health’s manufacturing network spans sites in the United Kingdom and North America, enabling scalable production and supply to meet global demand.
Founded in the mid-1990s and formerly listed on the AIM market of the London Stock Exchange in 2008, ECO Animal Health has grown through in-house research and strategic partnerships. In 2020, the company was acquired by Hebei Welcome Pharmaceutical & Chemical Co., strengthening its position within a broader pharmaceutical group. Today, ECO Animal Health serves customers across Europe, North America, Latin America, Asia-Pacific and the Middle East through a combination of direct distribution and partnerships with local veterinary channels.
AI Generated. May Contain Errors.